MedPath

Monitoring Vital Signs With a Wireless Ingestible Device in Subjects Undergoing Polysomnography

Not Applicable
Completed
Conditions
Sleep
Interventions
Device: Vitals Monitoring Pill System
Registration Number
NCT05183529
Lead Sponsor
Celero Systems, Inc.
Brief Summary

This Minimal Risk study is designed to evaluate the ability of the Celero ingestible Vitals Monitoring Pill (i.e., VM Pill) to measure respiration from within the gastrointestinal tract, in addition to performing an exploratory comparative analysis of data collected by the VM Pill and data collected from clinical monitoring sensors as part of polysomnography.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Healthy individuals ages 18 - 65 inclusive who are indicated for a polysomnography study.
Exclusion Criteria
  • Patients with a history of abdominal surgery and/or any condition that may impact the GI tract, including but not limited to:

    • Constipation
    • Esophageal stricture
    • Esophagitis
    • Gastritis
    • Gastric ulcers
    • Peptic ulcer
    • Gallstones
    • Celiac Disease
    • Crohn's Disease
    • Ulcerative Colitis
    • Irritable Bowel Syndrome
    • Diverticulitis
    • Colorectal cancer

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Patients undergoing polysomnographyVitals Monitoring Pill System-
Primary Outcome Measures
NameTimeMethod
Evaluate the ability of the VM Pill to monitor respiration from within the GI tractDuring polysomnography

Mean absolute error between respiratory rate measured by the VM Pill and respiratory rate measured by PSG monitoring equipment during periods of normal breathing while the patient is sleeping or at rest.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

West Virginia University

🇺🇸

Morgantown, West Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath